| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18d92c46f60af8af24e262b67381d7eb |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1796
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-68
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2016-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b489e83958b244abfcb173243f2b35a4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a08ff9afe793717b8d56e380c7873e9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_64f7362a82d5c8807bc7940d03aa67b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58e2ea7d87f07a64c3daf723e3af6a29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_01b69be148e702187faee1a00a12fb1c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81f8b0f56086e4cc1097850f8f0a4717 |
| publicationDate |
2021-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11123405-B2 |
| titleOfInvention |
Long-acting GLP-1R agonist as a therapy of neurological and neurodegenerative conditions |
| abstract |
The present invention relates to compositions and methods for treating neurodegenerative conditions using GLP-1r agonists. In certain embodiments, long-acting GLP-1r agonists have neuroprotective and disease modifying effects on the central nervous system. |
| priorityDate |
2015-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |